Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947167 | 1.00 | GRIN2B (0.64) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| SCHEMBL6001937 | 0.87 | GRIN2B (0.56) | GRIN2BOPRL1OPRM1LMNAALDH1A1 | |
| SCHEMBL9947176 | 0.85 | GRIN2B (0.68) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| SCHEMBL8673995 | 0.85 | GRIN2B (0.68) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| SCHEMBL9727205 | 0.85 | GRIN2B (0.68) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| SCHEMBL9506641 | 0.84 | GRIN2B (0.66) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| SCHEMBL9947164 | 0.84 | GRIN2B (0.66) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| SCHEMBL7436031 | 0.84 | GRIN2B (0.66) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| SCHEMBL9018525 | 0.84 | GRIN2B (0.66) | GRIN2BTSHROPRL1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL7938970 | 0.82 | GRIN2B (0.64) | GRIN2BTSHROPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1603395-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080170-A2 | AMINO SUBSTITUTED BENZO(HETERO)CYCLIC DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166984-A1 | Amino substituted benzo(hetero)cyclic derivatives | CBR3, L3MBTL3, BRS3 | GRIN2B 926/4885TSHR 1846/4885OPRL1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.